MBIO News and Press, Mustang Bio Inc. From 03/24/21

Mustang Bio (MBIO): FY GAAP EPS of -$1.14 misses by $0.13.As of December 31, 2020, Mustang’s cash and cash equivalents and restricted cash totaled $98.8 million, compared to $62.4 million as of December 31, 2019, an increase of $36.4 million year-to-date.Shares +1.63%.Press Release F...

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...

WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

Analysts Rate These Penny Stocks A Buy Right Now Finding the best penny stocks to buy right now can be a tall order. Not only are you dealing with noise in the market, but you’re also dealing with noise online. Set up any penny stock screener, and you’ll know what I&#x...

Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range of $16-$18.Underwriters' over-allotment is an additional 1,474,202 shares. Shares to kick-off trading t...

FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy WORCESTER, Mass.,...

Gainers: Aemetis (AMTX) +105%.Express (EXPR) +98%.MingZhu Logistics (YGMZ) +50%.TS Innovation Acquisitions (TSIA) +45%.IZEA Worldwide (IZEA) +43%.Orbital Energy (OEG) +36%.VYNE Therapeutics (VYNE) +35%.Accelerate Diagnostics (AXDX) +35%.Atossa Therapeutics (ATOS) +33%...

Today, we take an in-depth look at Mustang Bio whose shares are up some 60% over the past month. The rally was preceded by over $800,000 worth of insider buying in mid-December by the company's CEO and one director. Can the rally continue? We provide an investment analysis on...